<DOC>
	<DOCNO>NCT01505829</DOCNO>
	<brief_summary>This project seek develop quantitative imaging biomarker evaluate monitor treatment response ovarian cancer metastases assess potential monitoring treatment response . This involve standardise DW-MRI abdomen pelvis across multiple centre platform , assess reproducibility measurement patient plan neoadjuvant chemotherapy assess utility early response biomarker patient platinum-sensitive relapse due receive therapy carboplatin . Scanning measurement correlate histopathological marker tumour sample order link biomarker response mechanism .</brief_summary>
	<brief_title>Diffusion-weighted Imaging Study Cancer Ovary</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Histologically confirm ovarian , primary peritoneal fallopian tube cancer stage III IV Scheduled receive neoadjuvant chemotherapy ( carboplatin/cisplatin ) plan debulking surgery . Life expectancy le 6 month MRI contraindication Low grade heavily calcify disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>